Immunome amends BMS license, pays $20M and 4,425,487 shares to end royalties and acquire patents

Immunome Inc.

Immunome amended BMS license on Oct. 2, 2026, removing milestone/royalty obligations and assigning varegacestat (AL102) and AL101 patent rights to Immunome.
Immunome paid BMS $20.0 million cash and issued 4,425,487 common shares; after payment, Immunome has no milestone, royalty or other payment obligations to BMS under the License Agreement.
Stock Issuance Agreement requires Immunome to file a resale registration statement by Nov. 16, 2026, effective within 60 days or 5 business days if SEC does not review.
The 4,425,487 shares were issued under Section 4(a)(2) exemption and were not registered under the Securities Act; BMS received resale registration rights.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.